Rani Therapeutics (NASDAQ:RANI) Announces Earnings Results, Misses Expectations By $0.03 EPS

Rani Therapeutics (NASDAQ:RANI) announced its earnings results on Monday. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.03), Zacks reports. The company had revenue of $1.03 million during the quarter.

Rani Therapeutics Stock Down 7.4 %

Rani Therapeutics stock opened at $1.26 on Tuesday. The company has a debt-to-equity ratio of 2.34, a quick ratio of 1.60 and a current ratio of 1.60. The stock has a market cap of $72.18 million, a PE ratio of -1.19 and a beta of 0.14. Rani Therapeutics has a fifty-two week low of $1.24 and a fifty-two week high of $8.75. The firm’s 50-day simple moving average is $1.51 and its 200 day simple moving average is $1.83.

Analyst Ratings Changes

RANI has been the subject of a number of analyst reports. HC Wainwright restated a “buy” rating and set a $9.00 price objective on shares of Rani Therapeutics in a research report on Friday, February 7th. Canaccord Genuity Group restated a “buy” rating and set a $9.00 price target on shares of Rani Therapeutics in a report on Wednesday, February 26th. Five investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $12.33.

About Rani Therapeutics

Rani Therapeutics Holdings, Inc operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies.